Monoclonal Antibodies News
-
Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...
-
Optimizing Monoclonal Antibody Production: Temperature And Osmolality’s Impact, Upcoming Webinar Hosted By Xtalks
In this free webinar sponsored by Advanced Instruments, gain insights into advances in monoclonal antibody production technology and manufacturing strategies. Attendees will learn why temperature and osmolality in cell culture are critical parameters affecting cell growth, viability and the concentration of HCPs in the supernatant. The featured speaker will discuss how temperature and osmolality ...
-
Creative BioMart Unveils Comprehensive Lectin Portfolio for Diverse Research Applications
Creative BioMart, a renowned provider of innovative life science research solutions, proudly announces its extensive selection of lectins catering to a broad range of research endeavors. Lectins, a class of carbohydrate-binding proteins, hold immense significance in the scientific realm due to their diverse biological functions, encompassing cell adhesion, signal transduction, and immune ...
-
Biopharma PEG Assists ADC Development with Monodispersed PEGs
Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the field of Antibody-Drug Conjugate (ADC) development. The company now offers monodispersed Polyethylene Glycols (PEGs) on a scale ranging from grams to kilograms, and even on a ton scale. Notable PEGs include mPEG36-NH2, NH2-PEG24-COOH, OH-PEG9-OH, mPEG8-SPA, and more.ADCs ...
-
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay (NALFIA). These antibodies can specifically bind to small molecule labels and offer customers multiple choices, including Anti Digoxin monoclonal ...
-
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of new reagent solutions for herpesvirus research, including a range of Human Herpesviruses Antibodies designed to help researchers better understand the structure of Herpesvirus entry and develop new treatments and prevention strategies. The Herpesviridae are a large family ...
-
Alfa Chemistry-A New Supplier of Vaccine Excipients, Nucleic Acid Delivery Excipients and SARS-CoV-2 Detection Raw Materials
Alfa Chemistry, known as a chemical supplier for various high-quality chemicals and materials for both academia and the industry, has recently extended its offering scope to vaccine related products, including but not limited to: vaccine excipients, nucleic acid delivery excipients, cell culture media and pharmaceutical packaging. “Always bearing in mind that what customers truly need is the top ...
-
First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart therapeutic ...
-
Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,472,776 (the ‘776 patent) titled, “Novel Quinazolinones that Inhibit the Formation of Tau Oligomers.” The ‘776 ...
-
Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has recently closed an ...
-
Creative Diagnostics Expands Its Monoclonal Antibodies Offering to Customers
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the biotechnology industry, expanded its monoclonal antibodies capabilities and offerings to global customers, including over 1,000 of targets, carrier-free formulations, and conjugated antibodies. Monoclonal antibodies (mAbs) are generated by identical B cells that are cloned from a single parent cell. ...
-
Antengene Announces NDA Submission for XPOVIO in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications ...
-
Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technology
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
-
Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for Neuroscience’s Neuroscience meetings ...
-
Oral Presentation on Antengene`s Anti-CD24 Monoclonal Antibody ATG-031 Selected for SITC`s Top 100 Abstracts
Antengene is proud to announce that the oral presentation for ATG-031 (anti-CD24 monoclonal antibody) presented at the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022) was selected for the SITC top 100 abstracts. ATG-031 is a first-in-class, humanized anti-CD24 antibody. ATG-031 potently binds to CD24-postive tumor cells. ATG-031 blocks the interaction between CD24 and ...
-
Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRPα monoclonal antibody ES004, PD-L1/SIRPα bispecific antibody ...
By Elpiscience
-
Engineering antibody-antigen interfaces to improve therapeutic properties
Antibodies (immunoglobulins) are a key component of the mammalian immune response and are increasingly of interest as a means of therapy for several diseases. In fact, there are over 100 monoclonal antibodies that have been approved as drugs1. Despite this apparent success, there are issues with biopharmaceutical antibody research and development – not least the cost of goods. Although it ...
-
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer’s disease (AD). The studies did not meet their primary endpoint of slowing clinical decline. The level of beta-amyloid removal, the protein that builds up to make plaques ...
By MorphoSys AG
-
Pronalyse Supports Drug Discovery with the Launch of Biosimilar Analysis Solutions
Pronalyse is a protein characterization division of Creative Proteomics, an integrated CRO with rich experience in providing drug development services. Based on years of experience supporting the development of biosimilars, Creative Proteomics can provide comprehensive Biosimilar Analysis Solutions. A biosimilar is a biological product that is similar to an approved biological originator, ...
-
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors
ATG-017 is a small molecule ERK1/2 inhibitor and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-017. IND clearance enables Antengene to initiate the combination portion of the Phase I “ERASER” clinical trial in the United States (U.S.) to evaluate the safety, pharmacokinetics, and preliminary efficacy of ATG-017 combination therapy ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you